Pharmaceutical Technology

JANUARY 8, 2024

HH-006 is under clinical development by Huahui Health and currently in Phase I for Hepatitis D.

52

52

Hospital Pharmacy Europe

JUNE 27, 2023

The use of bulevirtide in patients with a chronic hepatitis D infection gave rise to a significant treatment response after 48 weeks, according to a recent phase 3 randomised trial. According to a recent systematic review , an estimated 12 million people worldwide have experienced hepatitis D infection.

Hospitals 52

Hospitals 52

Pharmaceutical Technology

JULY 4, 2022

Brii Biosciences (Brii Bio) has exercised an option for the acquisition of exclusive development and marketing rights for Vir Biotechnology’s investigational antibody, VIR-3434, for Hepatitis B in Greater China, under a partnership agreement.

111

111

Pharmaceutical Technology

OCTOBER 3, 2023

BW-20507 is under clinical development by Argo Biopharma Australia and currently in Phase II for Hepatitis B.

52

52

IDStewardship

APRIL 14, 2024

rCDI is defined as clinically significant diarrhea and a positive test confirming CDI within eight weeks of completing treatment for CDI. AGA Clinical Practice Guideline on Fecal Microbiota-Based Therapies for Select Gastrointestinal Diseases. Recommended Readings Peery AF, Kelly CR, Kao D, et al. Gastroenterology.

FDA 324

FDA Hospitals Communication 324

European Pharmaceutical Review

OCTOBER 21, 2022

Clinical trial results presented at the US IDWeek conference, revealed a three-dose series of the HEPLISAV-B vaccine prevents hepatitis B virus (HBV) in HIV patients not previously vaccinated against or infected with the virus. It will also evaluate ENGERIX-B, a GSK-manufactured three-dose hepatitis B vaccine series.

Vaccines 81

Vaccines Immunization FDA 81

European Pharmaceutical Review

NOVEMBER 9, 2022

GSK has announced study results from its Phase IIb trial ( NCT04449029 ) of bepirovirsen for chronic hepatitis B (CHB), indicating that the antisense oligonucleotide therapy could help treat CHB independently or in combination with nucleoside/nucleotide analogues (NAs). Further data on the chronic hepatitis B clinical trial.

91

91

Pharmaceutical Technology

DECEMBER 20, 2023

VTP-300 is under clinical development by Barinthus Biotherapeutics and currently in Phase II for Hepatitis B.

40

40

Pharmaceutical Technology

JANUARY 8, 2024

HH-006 is under clinical development by Huahui Health and currently in Phase I for Hepatitis D.

40

40

Pharma Times

DECEMBER 15, 2023

The funding builds on AstriVax’s €30m in seed funding for its vaccine platform AstriVax has announced that it has been awarded a total of €3m in funding from Flanders Innovation & Entrepreneurship (VLAIO) for its therapeutic vaccine targeting chronic hepatitis B.

Vaccines 38

Vaccines 38

Pharmaceutical Technology

OCTOBER 3, 2023

BW-20507 is under clinical development by Argo Biopharma Australia and currently in Phase II for Hepatitis B.

40

40

Hospital Pharmacy Europe

JULY 24, 2023

A single subcutaneous injection of zilebesiran, which inhibits hepatic angiotensinogen synthesis, maintained a reduced 24-hour ambulatory blood pressure for 24 weeks, an international research team has found. The study consisted of five different parts (A to E) but the current analysis focused on only three: Parts A, B and E.

Labelling 98

Labelling Hospitals 98

European Pharmaceutical Review

AUGUST 23, 2022

The researchers studied 254 VA patients who were diagnosed with PTSD and hepatitis C between October 1999 and September 2019. Participants received one combination of hepatitis C medications: including glecaprevir and pibrentasvir (GLE/PIB); ledipasvir and sofosbuvir (LDV/SOF); or sofosbuvir and velpatasvir (SOF/VEL). .

Department of Veterans Affairs 76

Department of Veterans Affairs Medical Records FDA 76

Pharmaceutical Technology

NOVEMBER 3, 2022

The US Food and Drug Administration (FDA) has granted approval for the supplemental new drug application (sNDA) of Gilead Sciences ’ Vemlidy (tenofovir alafenamide) to treat chronic hepatitis B virus (HBV) infection in paediatric patients.

FDA 52

FDA 52

European Pharmaceutical Review

MARCH 24, 2023

This treatment decreases hepatic steatosis and circulating lipids. He also shares key data from the ongoing Phase IIb clinical trial, and discusses the broader challenges of developing novel therapies in the NASH space. Data from clinical trials to-date suggests that pegozafermin could reduce hepatic fat and fibrosis.

90

90

Pharmaceutical Technology

JULY 5, 2022

Researchers at the UNC School of Medicine have discovered that hepatitis A virus (HAV) replication needs particular interactions between the human protein ZCCHC14 and TENT4 poly(A) polymerases, a group of enzymes. The post UNC team discovers interactions vital for hepatitis A virus replication appeared first on Pharmaceutical Technology.

Compounding 52

Compounding Dosage 52

Pharmafile

MARCH 28, 2023

Published date: 28/03/2023 Summary: - Completed Phase 1b/2a trial of VTP-300 met its primary and secondary endpoints - VTP-300 is the first antigen-specific immunotherapy shown to induce sustained reductions in Hepatitis B surface antigen (HBsAg) - Results will be presented at the upcoming European Association for the Study of the Liver (EASL) Congress (..)

Immunization 52

Immunization 52

Pharma Times

MARCH 28, 2023

Clinical trial involves patients with liver cirrhosis and hepatic encephalopathy

45

45

Med Ed 101

AUGUST 31, 2022

While it can be used for that purpose, it is fairly rare in clinical practice that you see it used for that indication. Lactulose, in my experience, is used more frequently for patients who have hepatic encephalopathy. I will share the most common lactulose clinical pearls that […].

40

40

European Pharmaceutical Review

JUNE 27, 2023

Diabetes cell therapy manufacture In Vertex’s first clinical programme, VX-880, recently released data showed all six patients treated with VX-880 engrafted islet cells, produced endogenous insulin (C-peptide). Operated by Lonza, the 130,000 square foot facility is anticipated to create up to 300 new jobs at peak capacity.

Immunization 97

Immunization 97

Pharmaceutical Technology

JUNE 5, 2023

Rezvilutamide is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Liver Failure (Hepatic Insufficiency). According to GlobalData, Phase I drugs for Liver Failure (Hepatic Insufficiency) does not have sufficient historical data to build an indication benchmark PTSR for Phase I.

40

40

Pharmaceutical Technology

MAY 10, 2023

XinThera’s therapy targeting MK2 is expected to enter clinical trials later in 2023. By adding an additional pipeline targeting oncology and inflammation diseases, the company expects that the deal will complement its existing clinical development priorities.

Immunization 52

Immunization 52

pharmaphorum

MARCH 10, 2022

Advance Combination Therapies, Outline Clinical Endpoints & Understand the Immunology Perspective to Achieve Functional Cures for Chronic Hepatitis B. This industry-orientated forum is timely positioned after EASL to reset standards after the latest readouts. Access the official agenda for more information.

Vaccines 52

Vaccines Immunization 52

European Pharmaceutical Review

SEPTEMBER 20, 2022

Zuranolone is an investigational oral 14-day treatment under clinical development for adult patients with MDD and postpartum depression. Zuranolone was generally well-tolerated with a safety profile consistent with prior clinical studies. Can Hepatitis C drugs reduce symptoms of PTSD?

Labelling 92

Labelling 92

pharmaphorum

JULY 26, 2022

The Hepatitis B (HBV) vaccine and human papillomavirus (HPV) vaccines are key examples. For Christopher Oelkrug, Director of Business Development for Advanced Clinical, it’s an exciting time to investigate the clinical efficacy of therapeutic cancer vaccines.

Vaccines 52

Vaccines Immunization 52

European Pharmaceutical Review

FEBRUARY 23, 2023

Meg Doherty, Director of WHO’s Global HIV, Hepatitis and Sexually Transmitted Infections Programmes in Geneva welcomed the results of the D2EFT study. For more than three million people living with HIV worldwide for whom first-line HIV treatment does not work, there is now evidence to support a range of treatment options.

97

97

Pharmaceutical Technology

MARCH 4, 2023

Vebreltinib is under clinical development by Apollomics and currently in Phase II for Solid Tumor. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. The therapeutic candidate is administered orally as a capsule.

40

40

Pharmaceutical Technology

MARCH 4, 2023

Vebreltinib is under clinical development by Apollomics and currently in Phase II for Renal Cell Carcinoma. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. The therapeutic candidate is administered orally as a capsule.

40

40

Pharmaceutical Technology

MARCH 4, 2023

Vebreltinib is under clinical development by Apollomics and currently in Phase II for Non-Small Cell Lung Cancer. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. The therapeutic candidate is administered orally as a capsule.

40

40

Pharmaceutical Technology

MARCH 4, 2023

Vebreltinib is under clinical development by Apollomics and currently in Phase II for Solid Tumor. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. The therapeutic candidate is administered orally as a capsule.

40

40

pharmaphorum

DECEMBER 6, 2021

Therefore extensive consideration of the clinical and cost-effectiveness of treatments must be made, to justify their value for money and their value to the health system. The combination treatment issue. The post How the combination treatment challenge impacts patients and how we are working together to solve it appeared first on.

52

52

Pharmaceutical Technology

JUNE 13, 2023

Patients with moderate hepatic impairment or who are taking moderate CYP3A4 [the main human enzyme responsible for phase I metabolism] inhibitors, may take 25mg once each night. Somnolence and headache are the most frequently reported adverse reactions observed in clinical trials.

Adverse Reactions 52

Adverse Reactions 52

pharmaphorum

APRIL 8, 2022

The Dublin-based pharma is paying $15 million upfront for global rights to Werewolf’s WTX-613, a prodrug of the cytokine interferon alfa-2b, which is still back n preclinical development and due to start its first clinical trials next year.

Immunization 105

Immunization 105

Pharmaceutical Technology

SEPTEMBER 20, 2022

Genfit has signed an exclusivity agreement for the acquisition of all the share capital and voting rights of Versantis, a Switzerland-based clinical-stage biotechnology firm, in a deal totalling $109m (Sfr105m). Versantis focuses on unmet liver ailment needs.

59

59

Pharmaceutical Technology

JULY 22, 2022

Muge Cevik’s tweet on the rise of unusual paediatric hepatitis cases. Muge Cevik, a clinical scientist, shared an article around the mystery of viral hepatitis cases in children. Retweets: 118. Username: Muge Cevik. Twitter handle: @mugecevik. Likes: 382. Retweets: 125. Helen Branswell’s tweet on the first US monkeypox case.

Vaccines 52

Vaccines Immunization Labelling Hospitals 52

pharmaphorum

SEPTEMBER 1, 2021

ASPIRO was placed under a clinical hold by the FDA last December after three deaths linked to liver dysfunction were seen in patients treated with a high dose (3.5 The FDA only relaxed its clinical hold on ASPIRO after Astellas and Audentes agreed to reduce dosing to the lower level. billion yen (around $532 million).

FDA 80

FDA 80

Pharmacy Is Right For Me

AUGUST 10, 2022

I joined the Janssen Pharmaceutical Companies of Johnson & Johnson in 2007 as a Medical Science Liaison from the Rainbow Center for Women, Children, and Families in Jacksonville, Florida, where I served as an HIV Clinical Specialist and Clinical Assistant Professor at the University of Florida School of Pharmacy.

Vaccines 130

Vaccines Pharmaceutical Companies Pharmaceutical Companies 130